Venture(US:VEMLY) Mei Ri Jing Ji Xin Wen·2025-05-21 10:51Core Viewpoint - Oriental Yanmei (Chengdu) Biotechnology Co., Ltd. is pursuing an IPO in Hong Kong despite a high debt-to-asset ratio of 123% and significant financial challenges, including projected losses of nearly 70 million yuan in 2024 and cash reserves of only 33.19 million yuan by the end of 2024 [1][9]. Company Overview - Founded in 2016, Oriental Yanmei focuses on regenerative medical devices and special medical foods, targeting a medical market worth hundreds of billions of yuan [1]. - The company's core product, "Tongyan Needle" XH301, is expected to receive approval in the second half of 2025, while competitors have already established a strong presence in this segment [1][6]. Financial Performance - The company reported revenues of approximately 12.88 million yuan in 2023 and 14.52 million yuan in 2024, primarily from non-core products, with a projected loss of nearly 70 million yuan in 2024 [8][9]. - The gross margin for 2023 and 2024 was 11.4% and 2.6%, respectively, with net losses of 63.5 million yuan and 69.4 million yuan attributed to R&D and operational expenses [9]. Market Potential - The regenerative medical materials injection market has grown from 200 million yuan in 2019 to 2.9 billion yuan in 2023, with a compound annual growth rate (CAGR) of 96.6%, expected to reach 18.5 billion yuan by 2032 [6]. - The special medical food market has also expanded from 2.7 billion yuan in 2019 to 6 billion yuan in 2023, with a CAGR of 17.2%, projected to reach 23.8 billion yuan by 2032 [8]. Management Team - The founder, Zhang Xinming, and key executives have a history of collaboration dating back to their time at Zhi Yuan Pharmaceutical, indicating a strong entrepreneurial bond [2][3]. - Zhang Xinming has extensive experience in the pharmaceutical industry, having worked at various companies including China Resources Sanjiu and Zhi Yuan Pharmaceutical [3][4]. Product Development - Oriental Yanmei has 13 candidate products in the regenerative medical device sector, with XH301 and XH321 currently undergoing registration review [6]. - The company has also developed 7 candidate products in the medical dressing and patch category, with one product already approved [6]. Competitive Landscape - The "Tongyan Needle" market is competitive, with several established players already having products approved, indicating a challenging environment for new entrants [7]. - The average approval cycle for regenerative medical devices is 3 to 5 years, adding to the urgency for Oriental Yanmei to secure funding and expedite its product launch [6][9].